Alvaro Díaz is a Senior Lecturer in Pharmacology at the Department of Physiology and Pharmacology of the University of Cantabria (UC) and a research member of Prof. Pazos group at the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC) and at the CIBERSAM (Centro de Investigación en Red en Salud Mental- Collaborative Research Network in Mental Health) https://www.cibersam.es/grupos/grupo-de-investigacion?id=14245. He obtained a MD degree in June 1986 (UC) and carried out his predoctoral training in the Department of Physiology and Pharmacology, studying the interaction between neuronal calcium channels and opioid receptors in pain signalling and processing, applying behavioural, neurochemical and molecular techniques and obtaining his PhD degree in 1994. To continue his research career in neuropharmacology, he was awarded a postdoctoral position (Welcome Trust, UK; January 1995 to June 1997) in Professor Dickenson´s lab (University College London), where he carried out "in vivo" electrophysiological techniques to study the role of spinal voltage-sensitive calcium channels, imidazoline I2 sites and neuronal nicotinic acetylcholine receptors in acute and persistent nociception. Back to Spain, he worked as a Research Associate (Department of Physiology and Pharmacology, UC 1997/2001) in research contracts with FAES FARMA S.A in studies directed to the "Valuation of active molecules on serotonergic and dopaminergic systems" using radiometric and "in vivo" electrophysiological techniques. In 2002, he obtained a "Ramón y Cajal" research position (Department of Physiology and Pharmacology, UC) to carry out a project dealing with the study of the modifications in serotonergic, noradrenergic and opioid neurotransmission systems in the animal models of depression in neuropathic pain. From 2006 to 2009, he was Associate Professor of Pharmacology in the University of Cantabria (Profesor Contratado Doctor) and in 2009 he was promoted to Senior Lecturer (Profesor Titular). From then until now, he has being involved in projects aimed to study the neurobiology of depression and to evaluate the behavioural, neurochemical and molecular actions of classic and potential antidepressants, using animal models of depression, and different techniques to assess the expression/functionality of receptors, and biomarkers of neurogenesis and neuroplasticity (orcid code: https://orcid.org/0000-0002-8783-4555). He has also carried out contract research projects with the pharmaceutical company Servier S.L. to evaluate the potential antidepressant effects of AMPA modulators. Regarding the academic activity, he is teaching Pharmacology in the Degree of Medicine and the Degree of Nursery, and he belongs to the lecturer's staff of the "Master's Degree in Initiation in Research in Mental Health" (CIBERSAM) and "Master's Degree in Molecular Biology and Medicine" (UC/UPV).
For this purpose, studies in laboratory animals, models of depression and psychosis, and in blood and postmortem samples from depressed and schizophrenic patients are carried out. Behavioural, pharmacological (in vivo assays, receptor labeling), cell biology (immunocytochemistry, neurogenesis), biochemical (second messengers, G proteins), electrophysiological (in vivo and slice recordings) and molecular approaches (gen silencing, transfected receptors) are used.
Santiago Mora, Elena Martín-González, Ángeles Prados-Pardo, José Joaquín Moreno-Casco, María José López-López, Fuencisla Pilar-Cuellar, Elena Castro, Álvaro Díaz, Pilar Flores, Margarita Moreno
Brain Behav Immun. 2020 Aug 13:S0889-1591(20)30083-0. doi: 10.1016/j.bbi.2020.08.010. Online ahead of print.
Pilar-Cuellar F, Castro E, Bretin S, Mocaer E, Pazos Á, Díaz Á.
Prog Neuropsychopharmacol Biol Psychiatry. 2019 Jul 13;93:205-213. doi: 10.1016/j.pnpbp.2019.04.005. Epub 2019 Apr 10.
Garro-Martínez E, Vidal R, Adell A, Díaz Á, Castro E, Amigó J, Gutiérrez-Lanza R, Florensa-Zanuy E, Gómez-Acero L, Taketo MM, Pazos Á, Pilar-Cuéllar F.
Mol Neurobiol. 2019 Dec 10. doi: 10.1007/s12035-019-01841-0. [Epub ahead of print]
Ibarra-Lecue I, Pilar-Cuéllar F, Muguruza C, Florensa-Zanuy E, Díaz Á, Urigüen L, Castro E, Pazos A, Callado LF.
2018 Nov;157:97-107. doi: 10.1016/j.bcp.2018.07.009. Epub 2018 Jul 17.
Varela MJ, Acanda de la Rocha AM, Díaz A, Lopez-Gimenez JF.
Pharmacol Biochem Behav. 2017 Dec;163:83-89. doi: 10.1016/j.pbb.2017.10.003. Epub 2017 Oct 10.
Jiménez-Sánchez L, Linge R, Campa L, Valdizán EM, Pazos Á, Díaz Á, Adell A. Neuropharmacology. 2016 Sep;108:91-102. doi: 10.1016/j.neuropharm.2016.04.020
Amigó J, Díaz A, Pilar-Cuéllar F, Vidal R, Martín A, Compan V, Pazos A, Castro E.
Neuropharmacology. 2016 Dec;111:47-58. doi: 10.1016/j.neuropharm.2016.08.037. Epub 2016 Aug 30.
Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á. Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017.
Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á.
Neuropharmacology. 2016 Apr;103:16-26. doi: 10.1016/j.neuropharm.2015.12.017. Epub 2015 Dec 19.
Vidal R, Castro E, Pilar-Cuéllar F, Pascual-Brazo J, Díaz A, Rojo ML, Linge R, Martín A, Valdizán EM, Pazos A.
Curr Pharm Des. 2014;20(23):3751-62.
Pilar-Cúellar F, Vidal R, Díaz A, Castro E, dos Anjos S, Vargas V, Romero B, Valdizán EM.
Curr Pharm Des. 2014;20(23):3776-94.
Instituto de Biomedicina y Biotecnología de Cantabria.
PCTCAN - Cl. Albert Einstein, 22